Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma

Jacob Schachter; Uriel Katz; Arie Mahrer; Dov Barak; Liat Ziegel Ben David; Jacob Nusbacher; Yehuda Shoenfeld

doi:10.1196/annals.1423.032

Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma

Jacob Schachter
, Uriel Katz
, Arie Mahrer
, Dov Barak
, Liat Ziegel Ben David
, Jacob Nusbacher
, Yehuda Shoenfeld^*

^*Corresponding author for this work

Clinical Departments

Sheba Medical Center at Tel Hashomer
GammaCan International, Inc.

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

20 Scopus citations

Abstract

We have previously reported studies performed both in vitro and in laboratory animals, as well as a case study in humans, suggesting that intravenous immunoglobulin (IVIG) may be beneficial in the treatment of malignancies, including metastatic melanoma. As part of a phase II open label trial, we have administered IVIG to nine patients with metastatic melanoma who had been heavily treated. In two of nine (22%) patients treated every 3 weeks with IVIG (1 g/kg body weight), the disease stabilized. One patient had stable disease for 8 months; the other for 3 months. No serious adverse events (AEs) attributable to IVIG were observed. We conclude that IVIG therapy may be useful for the treatment of metastatic melanoma. Furthermore, we suggest that the effects of IVIG therapy might be enhanced by its use as an adjuvant in patients without evidence of disease following surgery.

Original language	English
Title of host publication	Autoimmunity, Part B Novel Applications of Basic Research
Publisher	Blackwell Publishing Inc.
Pages	305-314
Number of pages	10
ISBN (Print)	1573317098, 9781573317092
DOIs	https://doi.org/10.1196/annals.1423.032
State	Published - Sep 2007

Publication series

Name	Annals of the New York Academy of Sciences
Volume	1110
ISSN (Print)	0077-8923
ISSN (Electronic)	1749-6632

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Adverse events
Cancer
IVIG
Intravenous immunoglobulin
Melanoma metastasis

Access to Document

10.1196/annals.1423.032

Cite this

Schachter, J., Katz, U., Mahrer, A., Barak, D., David, L. Z. B., Nusbacher, J., & Shoenfeld, Y. (2007). Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma. In Autoimmunity, Part B Novel Applications of Basic Research (pp. 305-314). (Annals of the New York Academy of Sciences; Vol. 1110). Blackwell Publishing Inc.. https://doi.org/10.1196/annals.1423.032

@inproceedings{8647ce0fd088425b906506787c418098,

title = "Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma",

abstract = "We have previously reported studies performed both in vitro and in laboratory animals, as well as a case study in humans, suggesting that intravenous immunoglobulin (IVIG) may be beneficial in the treatment of malignancies, including metastatic melanoma. As part of a phase II open label trial, we have administered IVIG to nine patients with metastatic melanoma who had been heavily treated. In two of nine (22\%) patients treated every 3 weeks with IVIG (1 g/kg body weight), the disease stabilized. One patient had stable disease for 8 months; the other for 3 months. No serious adverse events (AEs) attributable to IVIG were observed. We conclude that IVIG therapy may be useful for the treatment of metastatic melanoma. Furthermore, we suggest that the effects of IVIG therapy might be enhanced by its use as an adjuvant in patients without evidence of disease following surgery.",

keywords = "Adverse events, Cancer, IVIG, Intravenous immunoglobulin, Melanoma metastasis",

author = "Jacob Schachter and Uriel Katz and Arie Mahrer and Dov Barak and David, \{Liat Ziegel Ben\} and Jacob Nusbacher and Yehuda Shoenfeld",

year = "2007",

month = sep,

doi = "10.1196/annals.1423.032",

language = "אנגלית",

isbn = "1573317098",

series = "Annals of the New York Academy of Sciences",

publisher = "Blackwell Publishing Inc.",

pages = "305--314",

booktitle = "Autoimmunity, Part B Novel Applications of Basic Research",

}

Schachter, J, Katz, U, Mahrer, A, Barak, D, David, LZB, Nusbacher, J & Shoenfeld, Y 2007, Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma. in Autoimmunity, Part B Novel Applications of Basic Research. Annals of the New York Academy of Sciences, vol. 1110, Blackwell Publishing Inc., pp. 305-314. https://doi.org/10.1196/annals.1423.032

Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma. / Schachter, Jacob; Katz, Uriel; Mahrer, Arie et al.
Autoimmunity, Part B Novel Applications of Basic Research. Blackwell Publishing Inc., 2007. p. 305-314 (Annals of the New York Academy of Sciences; Vol. 1110).

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

TY - GEN

T1 - Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma

AU - Schachter, Jacob

AU - Katz, Uriel

AU - Mahrer, Arie

AU - Barak, Dov

AU - David, Liat Ziegel Ben

AU - Nusbacher, Jacob

AU - Shoenfeld, Yehuda

PY - 2007/9

Y1 - 2007/9

N2 - We have previously reported studies performed both in vitro and in laboratory animals, as well as a case study in humans, suggesting that intravenous immunoglobulin (IVIG) may be beneficial in the treatment of malignancies, including metastatic melanoma. As part of a phase II open label trial, we have administered IVIG to nine patients with metastatic melanoma who had been heavily treated. In two of nine (22%) patients treated every 3 weeks with IVIG (1 g/kg body weight), the disease stabilized. One patient had stable disease for 8 months; the other for 3 months. No serious adverse events (AEs) attributable to IVIG were observed. We conclude that IVIG therapy may be useful for the treatment of metastatic melanoma. Furthermore, we suggest that the effects of IVIG therapy might be enhanced by its use as an adjuvant in patients without evidence of disease following surgery.

AB - We have previously reported studies performed both in vitro and in laboratory animals, as well as a case study in humans, suggesting that intravenous immunoglobulin (IVIG) may be beneficial in the treatment of malignancies, including metastatic melanoma. As part of a phase II open label trial, we have administered IVIG to nine patients with metastatic melanoma who had been heavily treated. In two of nine (22%) patients treated every 3 weeks with IVIG (1 g/kg body weight), the disease stabilized. One patient had stable disease for 8 months; the other for 3 months. No serious adverse events (AEs) attributable to IVIG were observed. We conclude that IVIG therapy may be useful for the treatment of metastatic melanoma. Furthermore, we suggest that the effects of IVIG therapy might be enhanced by its use as an adjuvant in patients without evidence of disease following surgery.

KW - Adverse events

KW - Cancer

KW - IVIG

KW - Intravenous immunoglobulin

KW - Melanoma metastasis

UR - https://www.scopus.com/pages/publications/35748965294

U2 - 10.1196/annals.1423.032

DO - 10.1196/annals.1423.032

M3 - ???researchoutput.researchoutputtypes.contributiontobookanthology.conference???

C2 - 17911445

AN - SCOPUS:35748965294

SN - 1573317098

SN - 9781573317092

T3 - Annals of the New York Academy of Sciences

SP - 305

EP - 314

BT - Autoimmunity, Part B Novel Applications of Basic Research

PB - Blackwell Publishing Inc.

ER -

Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma

Abstract

Publication series

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this